Work

Combination Drug Therapy for the Management of Alzheimer’s Disease

Year: 2024

Type: article

Abstract: Alzheimer's disease (AD) is one of the most prevalent neurodegenerative diseases worldwide. It is the leading cause of dementia in both older and oldest old population. The standard treatment for AD dementia is based on two groups of drugs: cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and NMDA glutamate receptor modulator memantine. At moderate and severe stages of dementia, it is often necessary to use both a cholinergic inhibitor and memantine simultaneously. This review discusses current capabilities, efficacy and safety of combined therapy for Alzheimer's. It also covers details the features of using fixed combinations of donepezil and memantine in clinical practice.

Source: Russian Journal of Geriatric Medicine

DOI: 10.37586/2686-8636-2-2024-140-144

Authors: N. G. Dudchenko, E. A. Mkhitaryan

Institutions: Pirogov Russian National Research Medical University, Ministry of Health of the Russian Federation

Language: English

Topic: Dementia and Cognitive Impairment Research

Subfield: Psychiatry and Mental health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: diamond

OpenAlex ID: W4401034498

FWCI: 0.503

Cites: 26

Cited by: 2

Related to: 10